

Trying 3106016892...Open

Welcome to STN International! Enter x:x  
LOGINID:sssptal813nxml  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

8/468145

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 Expanded CAPLUS Coverage of US, Japanese, WIPO,  
EPO, and German patents  
NEWS 3 Feb 1 Addition of Machine-Translated Abstracts to CAPLUS  
NEWS 4 Feb 28 Patent Information Now Searchable in CAOLD  
NEWS 5 Mar 20 INPADOC: PRODUCER WARNING ABOUT DATA DELAYS  
NEWS 6 Mar 22 NEW FEATURES IN INPADOC - RANGE SEARCHING AND NEW  
SDI/UPDATE SEARCH FIELD  
NEWS 7 May 1 Beilstein Abstracts on STN - FILE BABS  
NEWS 8 May 1 RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED  
NEWS 9 May 1 AIDSLINE has been reloaded  
NEWS 10 May 1 Searching Y2-K compliant Patent Numbers  
NEWS 11 May 9 Sequence Similarity Batch Search in DGENE  
  
NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:39:34 ON 18 MAY 2000

=> file uspatfull wpids agricola

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'USPATFULL' ENTERED AT 17:40:11 ON 18 MAY 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 17:40:11 ON 18 MAY 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'AGRICOLA' ENTERED AT 17:40:11 ON 18 MAY 2000

=> e engel jurgen/au

E1	1	ENGEL JUERGEN/AU
E2	1	ENGEL JUNE/AU
E3	72 -->	ENGEL JURGEN/AU
E4	45	ENGEL K/AU
E5	6	ENGEL K E/AU
E6	2	ENGEL K G/AU
E7	40	ENGEL K H/AU
E8	1	ENGEL K W/AU
E9	2	ENGEL KARL/AU
E10	1	ENGEL KARL H/AU
E11	1	ENGEL KARL HEINZ/AU
E12	1	ENGEL KARSTEN/AU

=> s e3

L1 72 "ENGEL JURGEN"/AU

=> s l1 and lyophilili?

L2 11 L1 AND LYOPHILI?

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 11 DUP REM L2 (0 DUPLICATES REMOVED)

=> d bib ab 1-11

L3 ANSWER 1 OF 11 USPATFULL

AN 2000:50805 USPATFULL

TI Process for the preparation of immobilized and activity-stabilized complexes of LHRH antagonists

IN Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Deger, Wolfgang, Frankfurt, Germany, Federal Republic of  
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of  
Losse, Gunter, Dresden, Germany, Federal Republic of  
Naumann, Wolfgang, Zug, Germany, Federal Republic of  
Murgas, Sandra, Dresden, Germany, Federal Republic of

PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

PI US 6054555 20000425

AI US 1999-422990 19991022 (9)

RLI Division of Ser. No. US 1998-48244, filed on 26 Mar 1998

PRAI DE 1997-19712718 19970326

DT Utility

EXNAM Primary Examiner: Moezie, F. T.

LREP Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In this invention, a release-delaying system is to be developed for

LHRH antagonists, in particular for cetrorelix, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with cetrorelix. The cetrorelix polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P.sub.2 O.sub.5 in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a

suitable method. The cetorelix-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the cetorelix-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of cetorelix with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L3 ANSWER 2 OF 11 USPTFULL

AN 2000:15636 USPTFULL

TI Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation

IN Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Deger, Wolfgang, Frankfurt, Germany, Federal Republic of  
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of  
Losse, Gunter, Dresden, Germany, Federal Republic of  
Naumann, Wolfgang, Zug, Germany, Federal Republic of  
Murgas, Sandra, Dresden, Germany, Federal Republic of

PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

PI US 6022860 20000208

AI US 1998-48244 19980326 (9)

PRAI DE 1997-19712718 19970326

DT Utility

EXNAM Primary Examiner: Moezie, F. T.

LREP Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In this invention, a release-delaying system is to be developed for LHRH

antagonists, in particular for cetorelix, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers.

The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with cetorelix. The cetorelix polyamino

acid

complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P.sub.2 O.sub.5 in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a suitable method. The cetorelix-carboxylic acid

complexes

were also prepared from the aqueous solutions.

In the random liberation system, the acidic polyamino acids poly-Glu and

poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid.

In animal experiments, it was possible to confirm the activity of the cetorelix-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of cetorelix with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L3 ANSWER 3 OF 11 USPTFULL

AN 1998:48452 USPATFULL  
TI Lobaplatin trihydrate  
IN Gunther, Eckhard, Offenbach, Germany, Federal Republic of  
Wulf, Jens-Peter, Maintal, Germany, Federal Republic of  
**Engel, Jurgen**, Alzenau, Germany, Federal Republic of  
Kutscher, Bernhard, Maintal, Germany, Federal Republic of  
PA Asta Medica AG, Germany, Federal Republic of (non-U.S. corporation)  
PI US 5747534 19980505  
AI US 1996-714456 19960916 (8)  
PRAI DE 1994-4415263 19940415  
DT Utility  
EXNAM Primary Examiner: Nazario-Gonzalez, Porfirio  
LREP Schweitzer Cornman Gross & Bondell LLP  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1,2  
DRWN No Drawings  
LN.CNT 197  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Cis-[trans-1,2-cyclobutanebis (methylamine)-N,N']-[(2S)-lactate-  
O.sup.1,O.sup.2)-platinum (II) trihydrate (lobaplatin trihydrate) and  
its preparation.

L3 ANSWER 4 OF 11 USPATFULL  
AN 97:78416 USPATFULL  
TI Products for administering an initial high dose of Cetorelix and  
producing a combination package for use when treating diseases  
IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of  
Hilgard, Peter, Frankfurt, Germany, Federal Republic of  
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of  
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 5663145 19970902  
AI US 1994-354838 19941208 (8)  
PRAI DE 1993-4342091 19931209  
DT Utility  
EXNAM Primary Examiner: Russel, Jeffrey E.  
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 7  
DRWN No Drawings  
LN.CNT 227  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB For application during the treatment of benign and malign tumour  
diseases, the product according to the invention containing the initial  
dose of Cetorelix acetate and one or more maintenance doses of  
Cetorelix acetate, Cetorelix embonate or a slow-release form of  
Cetorelix, is used as a combination preparation for treatment to be  
administered at specific time intervals.

L3 ANSWER 5 OF 11 USPATFULL  
AN 93:69882 USPATFULL  
TI Ethylene-substituted phenylalkylethylenediamine-platinum (II or IV)  
derivatives and phenylalkylethylenediamines  
IN Brunner, Henri, Lappersdorf, Germany, Federal Republic of  
Hankofer, Peter, Koln, Germany, Federal Republic of  
Maiterth, Friedrich, Hagelstadt, Germany, Federal Republic of  
**Engel, Jurgen**, Alzenau, Germany, Federal Republic of  
Schumacher, Wolfgang, Langen, Germany, Federal Republic of  
Hilgard, Peter, Bielefeld, Germany, Federal Republic of  
Voegeli, Rainer, Bielefeld, Germany, Federal Republic of  
PA Asta Pharma AG, Germany, Federal Republic of (non-U.S. corporation)  
PI US 5238955 19930824  
AI US 1992-981475 19921125 (7)  
RLI Division of Ser. No. US 1991-683431, filed on 10 Apr 1991  
PRAI DE 1990-4011520 19900410

DT Utility  
EXNAM Primary Examiner: Prescott, Arthur C.  
LREP Cushman, Darby & Cushman  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1883

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N-CR.sub.2 < forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 < represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 < represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also

being

possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.

L3 ANSWER 6 OF 11 USPATFULL

AN 93:20739 USPATFULL

TI Ethylene-substituted phenylalkylethylene-diamine-platinum (II or IV) derivatives and phenylalkylethylenediamines

IN Brunner, Henri, Lappersdorf, Germany, Federal Republic of  
Hankofer, Peter, Cologne, Germany, Federal Republic of  
Maiterth, Friedrich, Hagelstadt, Germany, Federal Republic of  
**Engel, Jurgen**, Alzenau, Germany, Federal Republic of  
Schumacher, Wolfgang, Langen, Germany, Federal Republic of  
Hilgard, Peter, Bielefeld, Germany, Federal Republic of  
Voegeli, Rainer, Bielefeld, Germany, Federal Republic of

PA Asta Pharma AG, Germany, Federal Republic of (non-U.S. corporation)

PI US 5194644 19930316

AI US 1991-683431 19910410 (7)

PRAI DE 1990-4011520 19900410

DT Utility

EXNAM Primary Examiner: Prescott, Arthur C.

LREP Cushman, Darby & Cushman

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1893

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N--CR.sub.2 <forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural

part --CR.sub.2 < represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 < represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.

L3 ANSWER 7 OF 11 USPATFULL  
AN 91:46793 USPATFULL  
TI 1,2-bis (aminomethyl) cyclobutane-platinum complexes  
IN Schumacher, Wolfgang, Mannheim, Germany, Federal Republic of  
Respondek, Johannes, Hanau, Germany, Federal Republic of  
Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Pohl, Jorg, Halle, Germany, Federal Republic of  
Voegeli, Rainer, Bielefeld, Germany, Federal Republic of  
Hilgard, Peter, Bielefeld, Germany, Federal Republic of  
PA ASTA Pharma Aktiengesellschaft, United States (non-U.S. corporation)  
PI US 5023335 19910611  
AI US 1990-590610 19900925 (7)  
RLI Continuation of Ser. No. US 1989-295072, filed on 9 Jan 1989, now  
abandoned  
PRAI DE 1988-3800415 19880109  
DT Utility  
EXNAM Primary Examiner: Straub, Gary P.; Assistant Examiner: Hendrickson,  
Stuart L.  
LREP Cushman, Darby & Cushman  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 701  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB 1,2-Bis(aminomethyl)-cyclobutane-platinum complexes having an  
anti-tumor  
activity.

L3 ANSWER 8 OF 11 USPATFULL  
AN 88:14762 USPATFULL  
TI Tumor retarding (1,2-diphenyl-ethylenediamine)-platinum(II)-complexes  
IN Schonenberger, Helmut, Pentling, Germany, Federal Republic of  
von Angerer, Erwin, Grablfig, Germany, Federal Republic of  
Karl, Johann, Sunching, Germany, Federal Republic of  
Jennerwein, Margaretha, Regensburg, Germany, Federal Republic of  
Engel, Jurgen, Alzenau, Germany, Federal Republic of  
PA Asta-Werke Aktiengesellschaft, Bielefeld, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 4730068 19880308  
AI US 1986-831913 19860221 (6)  
PRAI DE 1985-3506507 19850223  
DT Utility  
EXNAM Primary Examiner: Sneed, Helen M. S.  
LREP Cushman, Darby & Cushman  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1356  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed antitumor active 1,2-diphenyl-ethylenediamine)-  
platinum(II)-complex of the general formula ##STR1## wherein R.sub.7 is  
hydrogen or C.sub.1 -C.sub.6 -alkyl and R.sub.2 is either (1) a halogen  
atom and the groups R.sub.1, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are  
the same or different and are hydrogen, halogen, trihalomethyl, C.sub.1  
-C.sub.6 -alkyl, hydrogen C.sub.1 -C.sub.6 -alkoxy, a C.sub.2 -C.sub.6  
-alkanoyloxy or a halo or C.sub.1 -C.sub.4 -alkanesulfonyloxy  
substituted C.sub.2 -C.sub.6 -alkanoyloxy group, or R.sub.2 is (2) a  
hydroxy group, a C.sub.1 -C.sub.6 -alkoxy group, a C.sub.2 -C.sub.6  
-alkanoyloxy group in the 4-position or a halo or C.sub.1 -C.sub.4  
-alkanesulfonyloxy substituted C.sub.2 -C.sub.6 -alkanoyloxy group and  
if R.sub.2 is (2) then the groups R.sub.1 and R.sub.3 which are the

same or differnt are in the 2 and 6 positions of the phenyl group and are  
halogen, trihalomethyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, a C.sub.1  
-C.sub.6 -alkoxy, C.sub.2 -C.sub.6 -alklanoyloxy group or a halo or  
C.sub.1 -C.sub.5 -alkanesulfonyloxy substituted C.sub.2 -C.sub.6  
-alkanoyloxy group, with the proviso that R.sub.1 can also be hydrogen  
and the groups R.sub.4, R.sub.5, and R.sub.6 are the same or different  
and are hydrogen, halogen, trihalomethyl, C.sub.1 -C.sub.6 -alkyl,  
hydroxy, C.sub.1 -C.sub.6 -alkoxy, a C.sub.2 -C.sub.6 -alkanoyloxy

group or a halo or C.sub.1 -C.sub.4 -alkanesulfonyloxy substituted C.sub.2  
-C.sub.6 -alkanoyloxy group and X is the equivalent of a  
physiologically compatible anion and process of their production.

L3 ANSWER 9 OF 11 USPATFULL

AN 87:89254 USPATFULL

TI Salts of oxazaphosphorine derivatives

IN Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Kleemann, Axel, Muhlheim, Germany, Federal Republic of  
Niemeyer, Ulf, Bielefeld, Germany, Federal Republic of  
Hilgard, Peter, Bielefeld, Germany, Federal Republic of  
Pohl, Joerg, Halle, Germany, Federal Republic of

PA Asta-Werke Aktiengesellschaft Chemische Fabrik, Bielefeld, Germany,  
Federal Republic of (non-U.S. corporation)

PI US 4716242 19871229

AI US 1985-704465 19850222 (6)

PRAI DE 1984-3407585 19840301

DT Utility

EXNAM Primary Examiner: Sutto, Anton H.

LREP Cushman, Darby & Cushman

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided new antitumor salts of oxazaphosphorine derivatives  
of the formula ##STR1## where R.sub.1, R.sub.2, and R.sub.3 are the

same or different and represent hydrogen, methyl, ethyl, 2-chloroethyl, or  
2-methanesulfonyloxyethyl and wherein at least two of these residues

are 2-chloroethyl and/or 2-methanesulfonyl-oxyethyl and A is the group  
--S--alk--SO.sub.3 H or --N(OH)--CONH--alk--CO.sub.2 H and alk  
represents a C.sub.2 -C.sub.6 -alkylene residue optionally containing a  
mercapto group, whereby alk also can be --CH.sub.2 -- in case there is

a carboxy group attached to the alk group, with homocysteinethiolactone

or .alpha.-amino-.epsilon.-caprolactam or a basic compound of the formula:  
##STR2## wherein R.sub.4 is a hydroxy group, an amino group or a

C.sub.1 -C.sub.6 -alkoxy group, R.sub.5 is hydrogen or a difluoromethyl group,

R.sub.6 is hydrogen, an indolyl-(3)-methyl residue, imidazolyl-(4)-methyl residue, a C.sub.1 -C.sub.10 -alkyl group or a C.sub.1 -C.sub.10 -alkyl group which is substituted by a hydroxy group, a C.sub.1 -C.sub.6 -alkoxy group, a mercapto group, a C.sub.1 -C.sub.6 -alkylmercapto group, a phenyl group, a hydroxy phenyl group, an amino-C.sub.1 -C.sub.6 -alkylmercapto group, an amino-C.sub.1 -C.sub.6 -alkoxy group, an amino group, an aminocarbonyl group, a ureido group (H.sub.2 NCONH--), a guanidino group or a C.sub.1 -C.sub.6 -alkoxycarbonyl group, or wherein R.sub.6 together with the structured portion >CR.sub.5 (NR.sub.7 R.sub.8) forms the proline residue, the 4-hydroxy-proline residue or the 2-oxo-3-amino-3-difluoromethyl-piperidine and the residues R.sub.7 and R.sub.8 represent hydrogen or C.sub.1 -C.sub.6 -alkyl residues.

L3 ANSWER 10 OF 11 USPATFULL

AN 87:76549 USPATFULL

TI Tumor retarding (1-benzyl-ethylenediamine)-platin (II)-complexes

IN Brunner, Henri, Lappersdorf, Germany, Federal Republic of  
Schonenberger, Helmut, Pentling, Germany, Federal Republic of  
Schmidt, Manfred, Gelnhausen, Germany, Federal Republic of  
Holzinger, Ulrich, Passau, Germany, Federal Republic of  
Unger, Gerfried, Frankfurt, Germany, Federal Republic of  
Engel, Jurgen, Alzenau, Germany, Federal Republic of

PA ASTA-Werke Aktiengesellschaft Chemische Fabrik, Bielefeld, Germany,  
Federal Republic of (non-U.S. corporation)

PI US 4704464 19871103

AI US 1986-831911 19860221 (6)

PRAI DE 1985-3506468 19850223

DT Utility

EXNAM Primary Examiner: Sneed, Helen M. S.

LREP Cushman, Darby & Cushman

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1389

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described (1-benzylethylenediamine)-platin(II)-complexes of the general formula: ##STR1## wherein the radicals R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are the same or different and are hydrogen, a C.sub.1 -C.sub.6 -alkyl group, a benzyl group, or a phenylethyl group, and B is a thienyl radical, an indolyl radical, an imidazolyl radical, or a phenyl radical substituted by the radicals R.sub.5, R.sub.6, an R.sub.7 which are the same or different and are hydrogen, halogen, trihalomethyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy, phenoxy, benzyloxy, C.sub.1 -C.sub.6 -alkanoyloxy, benzoyloxy, C.sub.1 -C.sub.6 -alkanesulfonyloxy, carboxy, C.sub.1 -C.sub.6 -carbalkoxy, cyano, aminocarboxyl, aminocarbonyl, which contains one or two C.sub.1 -C.sub.6 -alkyl radicals, C.sub.1 -C.sub.6 -alkylcarbonyl, nitro, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, (C.sub.1 -C.sub.6 -alkyl).sub.3 N.sup.+, C.sub.1 -C.sub.6 -alkanoylamino, C.sub.1 -C.sub.6 -alkyl-C.sub.1 -C.sub.6

-alkanoylamino,

C.sub.1 -C.sub.6 -alkanesulfonylamino, C.sub.1 -C.sub.6 -alkyl-C.sub.1 -C.sub.6 -alkanesulfonylamino, aminosulfonyl, aminosulfonyl which contains one or two C.sub.1 -C.sub.6 -alkyl radicals, C.sub.1 -C.sub.6 -alkoxysulfonyl (--SO.sub.2 --O--C.sub.1 -C.sub.6 -alkyl), sulfo (--SO.sub.3 H) or C.sub.1 -C.sub.6 -alkanesulfonyl and two of these groups can be the methylenedioxy group and X is the equivalent of a physiologically compatible anion, as well as optionally their salts

with

physiologically compatible cations and anions and process of their production.

L3 ANSWER 11 OF 11 USPATFULL  
 AN 86:38313 USPATFULL  
 TI (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds  
 IN Schonenberger, Helmut, Pentling, Germany, Federal Republic of  
 Wappes, Beate, Regensburg, Germany, Federal Republic of  
 Jennerwein, Margaretha, Regensburg, Germany, Federal Republic of  
 von Angerer, Erwin, Regensburg, Germany, Federal Republic of  
**Engel, Jurgen**, Alzenau, Germany, Federal Republic of  
 PA Degussa Aktiengesellschaft, Frankfurt, Germany, Federal Republic of  
 (non-U.S. corporation)  
 PI US 4598091 19860701  
 AI US 1984-580238 19840215 (6)  
 PRAI DE 1983-3305636 19830218  
 DT Utility  
 EXNAM Primary Examiner: Sneed, Helen M. S.  
 LREP Cushman, Darby & Cushman  
 CLMN Number of Claims: 14  
 ECL Exemplary Claim: 1,10  
 DRWN No Drawings  
 LN.CNT 971  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB There are prepared antitumor active (1,2-diphenyl-ethylenediamine)-  
 platinum (II) complex compounds of the formula ##STR1## where the  
 groups  
 R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and are  
 hydrogen, hydroxy groups, C.sub.1 -C.sub.6 -alkoxy groups, C.sub.2  
 -C.sub.6 -alkanoyloxy groups which optionally are substituted by  
 halogen  
 atoms or C.sub.1 -C.sub.4 -alkanesulfonyloxy groups or C.sub.3 -C.sub.6  
 -alkenoyloxy groups and at least one of R.sub.1, R.sub.2, R.sub.3 and  
 R.sub.4 is not hydrogen and X is the equivalent of a physiologically  
 compatible or pharmaceutically acceptable anion.

=> s cetorelix and hexitol

L4 0 CETRORELIX AND HEXITOL

=> s cetorelix

L5 31 CETRORELIX

=> s 15 and mannitol

L6 4 L5 AND MANNITOL

=> dup rem 16

PROCESSING COMPLETED FOR L6

L7 4 DUP REM L6 (0 DUPLICATES REMOVED)

=> d bib ab 1-4

L7 ANSWER 1 OF 4 USPATFULL  
 AN 1999:128511 USPATFULL  
 TI Pharmaceutical formulations for sustained drug delivery  
 IN Gefter, Malcolm L., Lincoln, MA, United States  
 Barker, Nicholas, Southborough, MA, United States  
 Musso, Gary, Hopkinton, MA, United States  
 Molineaux, Christopher J., Brookline, MA, United States  
 PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.  
 corporation)  
 PI US 5968895 19991019  
 AI US 1996-762747 19961211 (8)

DT Utility  
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner:  
Delacroix-Muirheid, C.  
LREP Lahive & Cockfield, LLP; Mandragouras, Amy E.; DeConti, Giulio A.  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 10  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 775  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Sustained delivery formulations comprising a water-insoluble complex of  
a peptide and a carrier macromolecule are disclosed. The formulations  
of  
the invention allow for loading of high concentrations of peptide in a  
small volume and for delivery of a pharmaceutically active peptide for  
prolonged periods, e.g., one month, after administration of the  
complex.  
The complexes of the invention can be milled or crushed to a fine  
powder. In powdered form, the complexes form stable aqueous suspensions  
and dispersions, suitable for injection. In a preferred embodiment, the  
peptide of the complex is an LHRH analogue, preferably an LHRH  
antagonist, and the carrier macromolecule is an anionic polymer,  
preferably carboxymethylcellulose. Methods of making the complexes of  
the invention, and methods of using LHRH-analogue-containing complexes  
to treat conditions treatable with an LHRH analogue, are also  
disclosed.

L7 ANSWER 2 OF 4 USPATFULL  
AN 1998:98932 USPATFULL  
TI DHA-pharmaceutical agent conjugates of taxanes  
IN Shashoua, Victor E., Brookline, MA, United States  
Swindell, Charles S., Merion, PA, United States  
Webb, Nigel L., Bryn Mawr, PA, United States  
Bradley, Matthews O., Laytonsville, MD, United States  
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)  
PI US 5795909 19980818  
AI US 1996-651312 19960522 (8)  
DT Utility  
EXNAM Primary Examiner: Jarvis, William R. A.  
LREP Wolf, Greenfield & Sacks, P.C.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 27 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 2451  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides conjugates of cis-docosahexaenoic acid and  
taxanes useful in treating cell proliferative disorders. Conjugates of  
paclitaxel and docetaxel are preferred.

L7 ANSWER 3 OF 4 USPATFULL  
AN 97:78416 USPATFULL  
TI Products for administering an initial high dose of **Cetrorelix**  
and producing a combination package for use when treating diseases  
IN Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Hilgard, Peter, Frankfurt, Germany, Federal Republic of  
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of  
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 5663145 19970902  
AI US 1994-354838 19941208 (8)  
PRAI DE 1993-4342091 19931209  
DT Utility  
EXNAM Primary Examiner: Russel, Jeffrey E.  
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 7

DRWN No Drawings

LN.CNT 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L7 ANSWER 4 OF 4 USPATFULL

AN 96:103974 USPATFULL

TI Compositions and methods for the treatment of male-pattern baldness

IN Tien, Henry C., 5660 SW. 58 Pl., Miami, FL, United States 33143

PI US 5574011 19961112

AI US 1995-416190 19950404 (8)

DT Utility

EXNAM Primary Examiner: Reamer, James H.

LREP Gonzalez, P.A., Olga

CLMN Number of Claims: 43

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 2046

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and compositions of LHRH analogs for the treatment of male-pattern baldness. Male-pattern baldness is treated by the administration of compositions containing LHRH analogs. The compositions may be administered by any of a variety of routes, including parenterally, (including subcutaneous, and intramuscular administration), topically, transdermally or transmucosally.

=> d his

(FILE 'HOME' ENTERED AT 17:39:34 ON 18 MAY 2000)

FILE 'USPATFULL, WPIDS, AGRICOLA' ENTERED AT 17:40:11 ON 18 MAY 2000

E ENGEL JURGEN/AU

L1 72 S E3

L2 11 S L1 AND LYOPHILI?

L3 11 DUP REM L2 (0 DUPLICATES REMOVED)

L4 0 S CETRORELIX AND HEXITOL

L5 31 S CETRORELIX

L6 4 S L5 AND MANNITOL

L7 4 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l5 and sterili?

L8 5 L5 AND STERILI?

=> d bib 1-5

L8 ANSWER 1 OF 5 USPATFULL

AN 1999:128511 USPATFULL

TI Pharmaceutical formulations for sustained drug delivery

IN Gefter, Malcolm L., Lincoln, MA, United States

Barker, Nicholas, Southborough, MA, United States

Musso, Gary, Hopkinton, MA, United States

Molineaux, Christopher J., Brookline, MA, United States

PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 5968895 19991019

AI US 1996-762747 19961211 (8)  
DT Utility  
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner:  
Delacroix-Muirheid, C.  
LREP Lahive & Cockfield, LLP; Mandragouras, Amy E.; DeConti, Giulio A.  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 10  
DRWN .2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 775  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 5 USPATFULL  
AN 1999:102518 USPATFULL  
TI Process to manufacture implants containing bioactive peptides  
IN Deghenghi, Romano, Cheseaux Dessus Bl, St. Cergue, Switzerland  
PI US 5945128 19990831  
AI US 1997-897942 19970721 (8)  
PRAI US 1996-25449 19960904 (60)  
DT Utility  
EXNAM Primary Examiner: Azpuru, Carlos A.  
LREP Pennie & Edmonds LLP  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 5 USPATFULL  
AN '97:78416 USPATFULL  
TI Products for administering an initial high dose of **Cetrorelix**  
and producing a combination package for use when treating diseases  
IN Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Hilgard, Peter, Frankfurt, Germany, Federal Republic of  
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of  
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 5663145 19970902  
AI US 1994-354838 19941208 (8)  
PRAI DE 1993-4342091 19931209  
DT Utility  
EXNAM Primary Examiner: Russel, Jeffrey E.  
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 7  
DRWN No Drawings  
LN.CNT 227  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 5 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD  
AN 1999-579322 [49] WPIDS  
CR 1998-193308 [17]  
DNC C1999-168473  
TI Preparation of pharmaceutical implants containing active biopeptides or  
analogues in a lactic acid/ glycolic acid copolymer carrier - uses aqueous  
slurry to wet the active component prior to blending with copolymer.  
DC A23 A96 B04 B07 D22  
IN DEGHENGHI, R  
PA (DEGH-I) DEGHENGHI R  
CYC 1  
PI US 5945128 A 19990831 (199949)\* 7p  
ADT US 5945128 A Provisional US 1996-25449 19960904, US 1997-897942 19970721  
PRAI US 1996-25449 19960904; US 1997-897942 19970721

L8 ANSWER 5 OF 5 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD  
AN 1994-265229 [33] WPIDS

DNC C1994-121294  
 TI Freeze-dried peptide compsns. - prepd. by freeze drying soln. of peptide in aq. acetic acid.  
 DC B04  
 IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B; BURKHARD, W; JUERGEN, E  
 PA (ASTA) ASTA MEDICA AG  
 CYC 30  
 PI EP 611572 A2 19940824 (199433)\* DE 5p  
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
 DE 4305225 A1 19940825 (199433) 5p  
 AU 9455235 A 19940825 (199436)  
 NO 9400564 A 19940822 (199436)  
 CA 2115943 A 19940820 (199439)  
 CZ 9400312 A3 19940914 (199439)  
 BR 9400617 A 19940927 (199440)  
 SK 9400195 A3 19940907 (199440)  
 FI 9400779 A 19940820 (199441)  
 JP 06271476 A 19940927 (199443) 5p  
 ZA 9401136 A 19941026 (199444) 12p  
 HU 67117 T 19950228 (199514)  
 EP 611572 A3 19950111 (199538)  
 AU 671881 B 19960912 (199644)  
 CN 1112019 A 19951122 (199737)  
 SG 46632 A1 19980220 (199822)  
 BR 1101004 A3 19980512 (199828)  
 CZ 284314 B6 19981014 (199847)  
 NZ 314707 A 19990225 (199914)  
 CZ 285768 B6 19991117 (200002)  
 ADT EP 611572 A2 EP 1994-101672 19940204; DE 4305225 A1 DE 1993-4305225  
 19930219; AU 9455235 A AU 1994-55235 19940217; NO 9400564 A NO 1994-564  
 19940218; CA 2115943 A CA 1994-2115943 19940218; CZ 9400312 A3 CZ  
 1994-312  
 19940214; BR 9400617 A BR 1994-617 19940218; SK 9400195 A3 SK 1994-195  
 19940218; FI 9400779 A FI 1994-779 19940218; JP 06271476 A JP 1994-20532  
 19940217; ZA 9401136 A ZA 1994-1136 19940218; HU 67117 T HU 1994-481  
 19940218; EP 611572 A3 EP 1994-101672 19940204; AU 671881 B AU 1994-55235  
 19940217; CN 1112019 A CN 1994-101378 19940218; SG 46632 A1 SG 1996-6874  
 19940204; BR 1101004 A3 BR 1997-1101004 19970514; CZ 284314 B6 CZ  
 1994-312  
 19940214; NZ 314707 A Div ex NZ 1994-250906 19940217, NZ 1994-314707  
 19940217; CZ 285768 B6 CZ 1998-974 19940214  
 FDT AU 671881 B Previous Publ. AU 9455235; CZ 284314 B6 Previous Publ. CZ  
 9400312; NZ 314707 A Div ex NZ 250906; CZ 285768 B6 Previous Publ. CZ  
 9800974  
 PRAI DE 1993-4305225 19930219

=> d ti ab 1-

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 5 USPATFULL

TI Pharmaceutical formulations for sustained drug delivery

AB Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations

of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex.

The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptide of the complex is an LHRH analogue, preferably an LHRH

antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L8 ANSWER 2 OF 5 USPATFULL

TI Process to manufacture implants containing bioactive peptides

AB A process for manufacturing a pharmaceutical composition for the delivery of an effective amount of a bioactive peptide or peptide

analog

over a period of 1 to 12 months. This process includes the steps of grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5:1 to a particle size of between about 50 and 150 .mu.m; **sterilizing** the ground copolymer with a dose of between about 1 and 2.5 Mrads of ionizing .gamma.-radiation; wetting the ground and **sterilized** copolymer with a sterile aqueous slurry of a bioactive peptide or peptide analog; aseptically blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of

the

bioactive peptide or peptide analog; drying the mixture at reduced pressure and at temperature not exceeding 25.degree. C.; aseptically extruding the dried mixture at a temperature between about 70 and 110.degree. C.; and aseptically cutting cylindrical rods of about 1 to

2

mm diameter and between about 10 and 25 mm in length from the extruded mixture to form the pharmaceutical implants.

L8 ANSWER 3 OF 5 USPATFULL

TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases

AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L8 ANSWER 4 OF 5 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

TI Preparation of pharmaceutical implants containing active biopeptides or analogs in a lactic acid/ glycolic acid copolymer carrier - uses aqueous slurry to wet the active component prior to blending with copolymer.

AB US 5945128 A UPAB: 19991124

NOVELTY - A process for incorporating an active biopeptide or analog into a long term release pharmaceutical implant having a lactic acid/ glycolic acid copolymer carrier using an aqueous slurry of active component is new

DETAILED DESCRIPTION - A process for making pharmaceutical implants capable of delivering a bioactive peptide or peptide analogue over 1-12 months comprises:

lactic (1) grinding a lactic acid/ glycolic acid copolymer, where the acid : glycolic acid ratio is 0-5:1, to a particle size of 50-150 micro

m;

(2) wetting the **sterilized** copolymer with a sterile aqueous slurry of the active component;

(3) blending the copolymer and the slurry to a homogenous mixture containing 10-50 % active component;

C; (4) drying the mixture under reduced pressure at less than 25 deg.

(5) extruding the dried mixture at 70-110 deg. C; and

(6) cutting the extrusion into cylindrical implant rods that are 1-2 mm in diameter and 10-25 mm long.

USE - Used in the manufacture of pharmaceutical implants especially

for the prolonged administration of drugs such as antagonists or agonists of Leuteinizing Hormone Releasing Hormone (LHRH), Gonadotrophin Releasing Hormone (GnRH), growth hormone releasing hormone, growth hormone releasing polypeptide, angiotensin, bombesin, bradykinin, cholecystokinin, enkephalin, neurokinin, tachykinin or Substance P; inhibitors of renin, proteases, metalloproteases, enkephalinase and atrial or brain

natriuretic

factor degrading enzyme. The method is also suitable for the manufacture of implants containing leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, **cetrorelix**, teverelix, ramorelix, antide, nictide, azeline B, azeline C and ganirelix.

ADVANTAGE - The formulations are not contaminated with organic solvents such as chloroform and methylene chloride and the use of water helps to achieve a uniform distribution of the drug. The powdery mixture is wettable to aid the manufacturing process and allows **sterilization** of the active ingredient prior to mixture with the polymer.

Dwg.0/3

L8 ANSWER 5 OF 5 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

TI Freeze-dried peptide compsns. - prepd. by freeze drying soln. of peptide in aq. acetic acid.

AB EP 611572 A UPAB: 19991110

Freeze-dried compsns. comprising a peptide of 3-15 amino acid units and opt. one or more matrix materials are characterised in that 1 pt. wt. of the peptide is dissolved in 100-10,000 pts. wt. of acetic acid and then transferred to water and the resulting soln. is freeze dried.

USE/ADVANTAGE - The compsns. esp. contain **cetrorelix** (EP 299402), which is used in the treatment of female infertility (for controlling ovulation prior to isolating egg cells for in-vitro fertilisation) and for gonad protection in male patients (e.g. undergoing radio- or chemotherapy). The aq. acetic acid soln. can be **sterilised** by filtration without gelation or hydrolysis of the peptide.

Dwg.0/0

=> e wichert burkhard/au

E1	1	WICHERT BERND/AU
E2	1	WICHERT BERNHARD/AU
E3	2 -->	WICHERT BURKHARD/AU
E4	5	WICHERT F/AU
E5	1	WICHERT G A/AU
E6	1	WICHERT GERHARD/AU
E7	1	WICHERT H/AU
E8	4	WICHERT H R/AU
E9	2	WICHERT HANS/AU
E10	2	WICHERT J M/AU
E11	2	WICHERT K/AU
E12	2	WICHERT KOBUS I/AU

=> s e3

L9 2 "WICHERT BURKHARD"/AU

=> d bib ab 1-2

L9 ANSWER 1 OF 2 USPATFULL

AN 1998:51216 USPATFULL

TI Ifosfamide lyophilizate preparations

IN **Wichert, Burkhard**, Bielefeld, Germany, Federal Republic of  
Sauerbier, Dieter, Oerlinghausen, Germany, Federal Republic of

Rawert, Jurgen, Werther, Germany, Federal Republic of  
PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 5750131 19980512  
AI US 1996-752069 19961119 (8)  
DT Utility  
EXNAM Primary Examiner: McKane, Joseph  
LREP Cushman Darby & Cushman IP Group Of Pillsbury Madison & Sutro, LLP  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 336

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to improved ifosfamide preparations which are distinguished in that as primary auxiliary a polysaccharide, in general a glycan, preferably dextran, starches or cellulose, in particular dextrans having an MW of 20,000 to 85,000, modified starches such as hydroxyethyl starch and chemically modified celluloses such as hydroxyethylcellulose and sodium carboxymethylcellulose, a glycol

ether, preferably polyethylene glycol, in particular polyethylene glycols having a molecular weight of 600 to 6000 or an amino acid, preferably alanine, leucine or glutamic acid, is added to them.

The improved ifosfamide preparation can also contain as an auxiliary a pharmaceutically customary buffer, for example acetate, citrate or tris buffer, preferably phosphate buffer.

In addition, improved ifosfamide preparations are obtained by addition of NaHCO.sub.3.

The ifosfamide preparations according to the invention can comprise one or a combination of several auxiliaries. Mesna can be added to the formulation as a uroprotector.

L9 ANSWER 2 OF 2 USPATFULL

AN 95:78172 USPATFULL

TI Stabilized hexadecylphosphocholine solutions in glycerol alkyl ethers

IN Engel, Jurgen, Alzenau, Germany, Federal Republic of  
Wolf-Heuss, Elisabeth, Mosbach, Germany, Federal Republic of  
Orth, Helmut, Hanau, Germany, Federal Republic of  
Wichert, Burkhard, Bielefeld, Germany, Federal Republic of  
Sauerbier, Dieter, Werther, Germany, Federal Republic of

PA Asta Medica AG, Germany, Federal Republic of (non-U.S. corporation)

PI US 5446033 19950829

AI US 1993-137964 19931019 (8)

PRAI DE 1992-4235911 19921023

DT Utility

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn

LREP Cushman Darby & Cushman

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Solutions of alkylphosphocholines in glycerol alkyl ethers having enhanced storage stability containing a buffer which maintains the pH value to a range between 4 and 6.